Brokerages Set Moderna, Inc. (NASDAQ:MRNA) PT at $126.49

Shares of Moderna, Inc. (NASDAQ:MRNA) have earned an average rating of “Hold” from the sixteen analysts that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $126.89.

A number of research analysts have commented on MRNA shares. William Blair restated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Thursday, May 2nd. Oppenheimer lifted their target price on shares of Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Jefferies Financial Group restated a “buy” rating and set a $125.00 price target on shares of Moderna in a research note on Tuesday, April 9th. Finally, UBS Group lifted their price objective on shares of Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research note on Tuesday.

Insider Buying and Selling

In other Moderna news, President Stephen Hoge sold 2,388 shares of Moderna stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the transaction, the president now directly owns 1,515,898 shares of the company’s stock, valued at approximately $143,358,473.86. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Moderna news, President Stephen Hoge sold 2,388 shares of the firm’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the sale, the president now directly owns 1,515,898 shares in the company, valued at approximately $143,358,473.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Shannon Thyme Klinger sold 544 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $99.05, for a total transaction of $53,883.20. Following the transaction, the insider now directly owns 9,267 shares of the company’s stock, valued at approximately $917,896.35. The disclosure for this sale can be found here. In the last 90 days, insiders sold 139,954 shares of company stock valued at $14,822,576. Insiders own 15.20% of the company’s stock.

Institutional Trading of Moderna

Institutional investors have recently modified their holdings of the company. International Assets Investment Management LLC lifted its position in Moderna by 6,528.9% in the fourth quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock worth $38,552,000 after purchasing an additional 381,808 shares during the period. abrdn plc raised its stake in shares of Moderna by 477.5% in the 4th quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after buying an additional 399,843 shares in the last quarter. Van ECK Associates Corp lifted its holdings in shares of Moderna by 19.2% during the 4th quarter. Van ECK Associates Corp now owns 270,774 shares of the company’s stock worth $26,929,000 after acquiring an additional 43,646 shares during the period. Invesco Ltd. boosted its position in shares of Moderna by 19.8% during the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after acquiring an additional 517,683 shares in the last quarter. Finally, Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD increased its stake in Moderna by 10.5% in the third quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD now owns 32,188 shares of the company’s stock valued at $3,252,000 after acquiring an additional 3,052 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Performance

MRNA stock opened at $121.89 on Thursday. The stock has a market cap of $46.71 billion, a P/E ratio of -7.78 and a beta of 1.57. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. The firm has a 50 day simple moving average of $106.59 and a 200 day simple moving average of $95.24. Moderna has a 52 week low of $62.55 and a 52 week high of $142.79.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company had revenue of $167.00 million during the quarter, compared to analyst estimates of $93.26 million. During the same quarter last year, the business posted $0.19 EPS. The company’s revenue for the quarter was down 91.0% on a year-over-year basis. Research analysts anticipate that Moderna will post -7.47 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.